Names | |
---|---|
Preferred IUPAC name (1S,9S)-1-Amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzopyranoindolizinoquinoline-10,13-dione | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C24H22FN3O4 |
Molar mass | 435.455 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references |
Exatecan is a drug which is a structural analog of camptothecin with antineoplastic activity.
A derivative is used in Trastuzumab deruxtecan.
Synthesis
References
- Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz, H; Tchekmedyian, NS; Feit, K; Ackerman, J; De Jager, RL; Eckhardt, SG; O'Reilly, EM (20 September 2006). "Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer". Journal of Clinical Oncology. 24 (27): 4441–7. doi:10.1200/JCO.2006.07.0201. PMID 16983112.
- H. Terasawa, A. Ejima, S. Ohsuki, K. Uoto, U.S. Patent 5,834,476 (1998).
This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |